IMVT
Immunovant, Inc.
NASDAQ · USHealthcareBiotechnology
$39.92-0.84%
Price as of Jul 20, 2026
IMVT valuation
Immunovant, Inc. valuation
Trailing, forward and enterprise-value multiples for the requested listing.
Forward multiples
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 564.39x
Trailing multiples
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 9.53x
- Price / sales
- —
- Price / cash flow
- -19.95x
Enterprise value
- Enterprise value
- $7.2B
- EV / sales
- —
- EV / EBITDA
- -14.30x
- EV / EBIT
- -13.55x
- Market cap
- $8.1B
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.